Tempest Therapeutics, Inc. Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense
Tempest Therapeutics, Inc. (TPST) reported Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense of $100.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense · last filed 2026-08-13
- Tempest Therapeutics, Inc. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2026-03-31 was $100.00K.
| Period end | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 3 month | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 12 month |
|---|---|---|
| 2026-03-31 | $100.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $800.00K 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |